Onrust, Susan V.; Lamb, Harriet M.; Barman Balfour, Julia A.
July 1999
Drugs;Jul1999, Vol. 58 Issue 1, p79
Academic Journal
â–´ Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells. &utrif: Rituximab reduced peripheral B lymphocyte counts by ≈90% within 3 days in patients with relapsed indolent lymphoma. Counts remained depleted for 6 months and recovered by months 9 to 12 after 4 doses of rituximab 375 mg/m[SUP2] once weekly. &utrif: Clinical response rates were 46 and 48% in 2 non-comparative trials in patients with relapsed indolent lymphoma. The rate of response to rituximab appeared to be markedly higher in patients with follicular lymphoma than in those with small lymphocytic disease (56 or 60% versus 13 or 15%). &utrif: 85 to 94% of patients reported adverse events during clinical trials of rituximab; 90% of events were mild or moderate. The most common adverse event, a transient set of flu-like symptoms during the first infusion in approximately 50 to 87% of patients, generally resolved completely in <3 hours. Diphenhydramine and/or paracetamol was administered to some patients. &utrif: In 10% of patients, the flu-like symptoms during the first infusion were accompanied by bronchospasm and/or hypotension or severe cytokine release syndrome. Patients were generally able to complete treatment after these symptoms resolved.


Related Articles

  • CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Álvaro-Naranjo, T.; Jaén-Martínez, J.; Gumá-Padró, J.; Bosch-Príncep, R.; Salvadó-Usach, M. T. // Annals of Hematology;Sep2003, Vol. 82 Issue 9, p585 

    Rituximab is a monoclonal antibody against the CD20 molecule which is used to treat B-cell lymphomas. In 60% of low-grade B lymphomas in which rituximab was effective at first, there was no clinical response in a second treatment and a few cases of follicular lymphomas (FL) with transformation...

  • Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma. Grillo-Lopez, A.J.; White, C.A.; Dallaire, B.K.; Varns, C.L.; Shen, C.D.; Wei, A.; Leonard, J.E.; McClure, A.; Weaver, R.; Cairelli, S.; Rosenberg, J. // Current Pharmaceutical Biotechnology;Jul2000, Vol. 1 Issue 1, p1 

    Rituximab, a genetically engineered monoclonal chimeric antibody, targets the CD20 antigen expressed on B cells. It was approved by the US Food and Drug Administration on November 26, 1997, for the indication of relapsed or refractory, CD20-positive, B-cell, low-grade or follicular non-Hodgkins...

  • Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Borgerding, Andrea; Hasenkamp, Justin; Glaß, Bertram; Wulf, Gerald; Trümper, Lorenz // Annals of Hematology;Mar2010, Vol. 89 Issue 3, p283 

    Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line...

  • Rituximab therapy in malignant lymphoma. Coiffier, B. // Oncogene;5/28/2007, Vol. 26 Issue 25, p3603 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients....

  • Genetic lesions in diffuse large B-cell lymphomas. Testoni, M.; Zucca, E.; Young, K. H.; Bertoni, F. // Annals of Oncology;Jun2015, Vol. 26 Issue 6, p1069 

    Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35%-40% of all cases. The combination of the anti-CD20 monoclonal antibody rituximab with anthracycline-based combination chemotherapy (R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine...

  • Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Lemieux, Bernard; Bouafia, Fadhela; Thieblemont, Catherine; Hequet, Olivier; Arnaud, Philippe; Tartas, Sophie; Traulle, Catherine; Salles, Gilles; Coiffier, Bertrand // Hematology Journal;2004, Vol. 5 Issue 6, p467 

    The purpose of this study was to evaluate retrospectively the effect of a second treatment with rituximab for patients who progressed after a response to a first treatment. We analysed the charts of 41 patients treated at CHU Lyon-Sud between 1997 and May 2003. Patients were treated with...

  • A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Arcaini, L; Orlandi, E; Alessandrino, Ep; Iacona, I; Brusamolino, E; Bonfichi, M; Bernasconi, P; Calatroni, S; Tenore, A; Montanari, F; Troletti, D; Pascutto, C; Regazzi, M; Lazzarino, M // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 2, p175 

    Summary:We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of HD chemotherapy and autotransplant. After two courses of debulking...

  • Cost-Effectiveness Analysis of the Addition of Rituximab to CHOP in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma. Ferrara, Felicetto; Ravasio, Roberto // Clinical Drug Investigation;2008, Vol. 28 Issue 1, p55 

    BACKGROUND: and objective: Diffuse large-B-cell lymphoma (DLBCL) is an aggressive form of lymphoma. It accounts for 30–40% of all new cases of non-Hodgkin’s lymphoma and is the subtype with the highest overall incidence. Before the development of monoclonal...

  • Immunothérapie des lymphomes. Reyes, F. // Oncologie;mai2006, Vol. 8 Issue 4, p331 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of aggressive and indolent, untreated or relapsed B-cell lymphomas. The combination of rituximab with chemotherapy, such as R-CHOP, has the highest efficacy ever described with any chemotherapy regimen....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics